CA2541903A1 - Methode de diagnostic et de traitement - Google Patents

Methode de diagnostic et de traitement Download PDF

Info

Publication number
CA2541903A1
CA2541903A1 CA002541903A CA2541903A CA2541903A1 CA 2541903 A1 CA2541903 A1 CA 2541903A1 CA 002541903 A CA002541903 A CA 002541903A CA 2541903 A CA2541903 A CA 2541903A CA 2541903 A1 CA2541903 A1 CA 2541903A1
Authority
CA
Canada
Prior art keywords
pkc
cancer
euphorbia
cells
pep005
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002541903A
Other languages
English (en)
Inventor
Steven Martin Ogbourne
Peter Gordon Parsons
Janet Lord
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peplin Research Pty Ltd
Original Assignee
Peplin Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peplin Research Pty Ltd filed Critical Peplin Research Pty Ltd
Priority to CA002541903A priority Critical patent/CA2541903A1/fr
Publication of CA2541903A1 publication Critical patent/CA2541903A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002541903A 2006-04-20 2006-04-20 Methode de diagnostic et de traitement Abandoned CA2541903A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002541903A CA2541903A1 (fr) 2006-04-20 2006-04-20 Methode de diagnostic et de traitement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002541903A CA2541903A1 (fr) 2006-04-20 2006-04-20 Methode de diagnostic et de traitement

Publications (1)

Publication Number Publication Date
CA2541903A1 true CA2541903A1 (fr) 2007-10-20

Family

ID=38606719

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002541903A Abandoned CA2541903A1 (fr) 2006-04-20 2006-04-20 Methode de diagnostic et de traitement

Country Status (1)

Country Link
CA (1) CA2541903A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085189A1 (fr) * 2010-12-22 2012-06-28 Leo Pharma A/S Ingénol-3-acylates i
WO2012083954A1 (fr) * 2010-12-22 2012-06-28 Leo Pharma A/S 3-acyl-ingénols ii
WO2012083953A1 (fr) * 2010-12-22 2012-06-28 Leo Pharma A/S Ingénol-3-acylates iii et ingénol-3-carbamates
CN102597778A (zh) * 2009-10-30 2012-07-18 学校法人庆应义塾 抗癌剂感受性的判定方法
RU2575350C2 (ru) * 2010-12-22 2016-02-20 Лео Лэборетериз Лимитед 3-ацилингенолы ii
KR101914460B1 (ko) 2010-07-20 2018-11-05 레오 라보라토리즈 리미티드 인게놀-3-안젤레이트의 제조방법

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102597778B (zh) * 2009-10-30 2016-03-02 学校法人庆应义塾 抗癌剂感受性的判定方法
CN102597778A (zh) * 2009-10-30 2012-07-18 学校法人庆应义塾 抗癌剂感受性的判定方法
US9459254B2 (en) 2009-10-30 2016-10-04 Keio University Method for determining sensitivity to an anticancer agent
EP3640236A1 (fr) * 2010-07-20 2020-04-22 Leo Laboratories Limited Procédés de production d'ingénol-3-angélate
EP2595948B1 (fr) * 2010-07-20 2019-09-04 Leo Laboratories Limited Procédé de production d'ingénol-3-angélate
KR101914460B1 (ko) 2010-07-20 2018-11-05 레오 라보라토리즈 리미티드 인게놀-3-안젤레이트의 제조방법
RU2572549C2 (ru) * 2010-12-22 2016-01-20 Лео Лэборетериз Лимитед Ингенол-3-ацилаты iii и ингенол-3-карбаматы
US9388124B2 (en) 2010-12-22 2016-07-12 Leo Laboratories Limited Ingenol-3-acylates I
US9102687B2 (en) 2010-12-22 2015-08-11 Leo Laboratories Limited Ingenol-3-acylates III and ingenol-3-carbamates
AU2011348637B2 (en) * 2010-12-22 2015-08-20 Leo Laboratories Limited Ingenol-3-acylates III and ingenol-3-carbamates
WO2012085189A1 (fr) * 2010-12-22 2012-06-28 Leo Pharma A/S Ingénol-3-acylates i
RU2575350C2 (ru) * 2010-12-22 2016-02-20 Лео Лэборетериз Лимитед 3-ацилингенолы ii
RU2575349C2 (ru) * 2010-12-22 2016-02-20 Лео Лэборетериз Лимитед Ингенол-3-ацилаты i
JP2014512331A (ja) * 2010-12-22 2014-05-22 レオ・ラボラトリーズ・リミテッド インゲノール−３−アシラートｉｉｉおよびインゲノール−３−カルバメート
JP2016029081A (ja) * 2010-12-22 2016-03-03 レオ・ラボラトリーズ・リミテッドＬｅｏ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ インゲノール−３−アシラートｉｉｉおよびインゲノール−３−カルバメート
AU2011348638B2 (en) * 2010-12-22 2015-05-21 Leo Laboratories Limited 3-acyl-ingenols II
JP2014507396A (ja) * 2010-12-22 2014-03-27 レオ・ラボラトリーズ・リミテッド イノゲノール−３−アシラートｉ
AU2015210441B2 (en) * 2010-12-22 2016-10-06 Leo Laboratories Limited Ingenol-3-acylates iii and ingenol-3-carbamates
US9656945B2 (en) 2010-12-22 2017-05-23 Leo Laboratories Limited 3-acyl-ingenols II
US9708286B2 (en) 2010-12-22 2017-07-18 Leo Laboratories Limited Ingenol-3-acylates III and ingenol-3-carbamates
JP2014507393A (ja) * 2010-12-22 2014-03-27 レオ・ラボラトリーズ・リミテッド ３−アシル−イノゲノールｉｉ
WO2012083953A1 (fr) * 2010-12-22 2012-06-28 Leo Pharma A/S Ingénol-3-acylates iii et ingénol-3-carbamates
WO2012083954A1 (fr) * 2010-12-22 2012-06-28 Leo Pharma A/S 3-acyl-ingénols ii

Similar Documents

Publication Publication Date Title
Butturini et al. Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs
Kaur et al. Adenosine A1 receptor protects against cisplatin ototoxicity by suppressing the NOX3/STAT1 inflammatory pathway in the cochlea
Jiang et al. Anti-tumor effects of osthole on ovarian cancer cells in vitro
Bonet-Ponce et al. On the mechanism underlying ethanol-induced mitochondrial dynamic disruption and autophagy response
Grommes et al. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor γ agonist treatment
Xie et al. The protective effect of resveratrol in the transmission of neuropathic pain mediated by the P2X7 receptor in the dorsal root ganglia
Huang et al. Protein kinase CK2α catalytic subunit ameliorates diabetic renal inflammatory fibrosis via NF-κB signaling pathway
US20080069809A1 (en) Compositions and methods for the diagnosis and treatment of cancer
Zhang et al. Protective mechanism of Taxifolin for chlorpyrifos neurotoxicity in BV2 cells
Ma et al. Promotion of Momordica Charantia polysaccharides on neural stem cell proliferation by increasing SIRT1 activity after cerebral ischemia/reperfusion in rats
Ye et al. Secondary metabolites of mulberry leaves exert anti-lung cancer activity through regulating the PD-L1/PD-1 signaling pathway
Wang et al. Total flavonoid aglycones extract in Radix scutellariae inhibits lung carcinoma and lung metastasis by affecting cell cycle and DNA synthesis
Feng et al. Up-regulation of P-gp via NF-κB activation confers protection against oxidative damage in the retinal pigment epithelium cells
CA2541903A1 (fr) Methode de diagnostic et de traitement
US8889672B2 (en) Compounds, formulations, and methods of protein kinase C inhibition
Gao et al. Adenosine protects cardiomyocytes against acrolein-induced cardiotoxicity by enhancing mitochondrial homeostasis, antioxidant defense, and autophagic flux via ERK-activated FoxO1 upregulation
Wu et al. Ginsenoside Rh2 inhibits CBP/p300-mediated FOXO3a acetylation and epilepsy-induced oxidative damage via the FOXO3a–KEAP1–NRF2 pathway
Xiaoling et al. TRIM40 ameliorates diabetic retinopathy through suppressing inflammation via Reelin/DAB1 signaling disruption: A mechanism by proteasomal degradation of DAB1
Shi et al. Aucubin inhibits hepatic stellate cell activation through stimulating Nrf2/Smad7 axis
Tian et al. Aurora kinase A inhibition plus Tumor Treating Fields suppress glioma cell proliferation in a cilium-independent manner
Shen et al. Targeting of ubiquitination and degradation of KLF15 by E3 ubiquitin ligase KBTBD7 regulates LPS-induced septic brain injury in microglia
JP2014129341A (ja) マルチキナーゼ阻害剤、抗癌剤、抗転移剤、薬剤耐性抑制剤、疼痛抑制剤及び止痒薬
AU2006201661A1 (en) A method of diagnosis and treatment
AU2015352041B2 (en) Titled extracts of Cynara scolymus and uses thereof
Khayat et al. Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea

Legal Events

Date Code Title Description
FZDE Discontinued